"Ovarian Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Descriptor ID |
D010051
|
| MeSH Number(s) |
C04.588.322.455 C13.351.500.056.630.705 C13.351.937.418.685 C19.344.410 C19.391.630.705
|
| Concept/Terms |
Ovarian Neoplasms- Ovarian Neoplasms
- Neoplasm, Ovarian
- Ovarian Neoplasm
- Ovary Neoplasms
- Neoplasm, Ovary
- Neoplasms, Ovary
- Ovary Neoplasm
- Neoplasms, Ovarian
Ovary Cancer- Ovary Cancer
- Cancer, Ovary
- Cancers, Ovary
- Ovary Cancers
- Ovarian Cancer
- Cancer, Ovarian
- Cancers, Ovarian
- Ovarian Cancers
- Cancer of Ovary
- Cancer of the Ovary
|
Below are MeSH descriptors whose meaning is more general than "Ovarian Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Ovarian Neoplasms".
This graph shows the total number of publications written about "Ovarian Neoplasms" by people in this website by year, and whether "Ovarian Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 5 | 0 | 5 |
| 2012 | 1 | 2 | 3 |
| 2013 | 5 | 0 | 5 |
| 2014 | 5 | 1 | 6 |
| 2015 | 2 | 0 | 2 |
| 2016 | 4 | 0 | 4 |
| 2017 | 3 | 0 | 3 |
| 2018 | 1 | 1 | 2 |
| 2019 | 3 | 2 | 5 |
| 2020 | 3 | 0 | 3 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ovarian Neoplasms" by people in Profiles.
-
Transcriptome analysis of newly established carboplatin-resistant ovarian cancer cell model reveals genes shared by drug resistance and drug-induced EMT. Br J Cancer. 2023 03; 128(7):1344-1359.
-
Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants. J Clin Oncol. 2022 05 10; 40(14):1529-1541.
-
Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in BRCA1/2: results of the observational AGO-TR1 study (NCT02222883). J Med Genet. 2022 03; 59(3):248-252.
-
Clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancer. Arch Gynecol Obstet. 2020 04; 301(4):1027-1035.
-
Circulating cell-free DNA variables as marker of ovarian cancer patients: A pilot study. Cancer Biomark. 2020; 28(2):159-167.
-
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(=3) chemotherapy - The GCIG symptom benefit study (SBS). Gynecol Oncol. 2020 01; 156(1):45-53.
-
EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM. Mol Cancer Res. 2020 02; 18(2):278-286.
-
Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer. Breast Cancer Res. 2019 04 29; 21(1):55.
-
Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883). J Med Genet. 2019 09; 56(9):574-580.
-
IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner. Nucleic Acids Res. 2019 01 10; 47(1):375-390.
MeSH information
